https://doi.org/10.55788/04c0273a
Prof. Mark Walters (University of California, CA, USA) presented up to 8 years of follow-up efficacy and safety data of 63 patients with TDT who received beti-cel infusion therapy [1]. Transfusion independence was defined as a haemoglobin (Hb) level ≥9 g/dL without packed red blood cell transfusions for ≥12 months.
The peripheral blood vector copy number (VCN) per cell was stable and durable over time, especially in phase 3 studies, in which patients received optimised beti-cel infusion doses. Similarly, total Hb levels and therapy-derived HbA-T87Q levels were stable and durable (mean of approximately 12 g/dL and 9 g/dL) for patients who were included in phase 3 studies. Prof. Walters showed that the effect was independent of age and genotype. Furthermore, an exploratory analysis suggested that a percentage of 62% transduced cells increased the likelihood of achieving transfusion independence. Finally, 19% of the patients in phase 3 trials had ≥1 adverse event (AE) possibly related to beti-cel infusion therapy. Hepatic veno-occlusive disease occurred in 11% of the patients, but these events were resolved after treatment.
In another presentation, Prof. Franco Locatelli (University of Rome, Italy) reported the 3-year follow-up data of the LTF-303 study (NCT02633943), that investigated patient-reported outcomes in patients with TDT who received beti-cel infusion therapy (n=57) [2]. For patients who had reached transfusion independence, the SF-36 physical component score and mental component score were 55.7 and 56.3 at 3 years, which was a raise from the baseline levels of 53.8 and 50.9, respectively. A slight drop in SF-36 scores was observed in patients who had not achieved transfusion independence. In paediatric patients who reached transfusion independence (n=22), the mean PedsQL total score increased from 78.3 at baseline to 90.6 at 3 years. For those who did not achieve transfusion independence, no change in mean PedsQL total score was reported. Three years after treatment, data showed positive trends in employment/employment seeking rates (67% to 93%), school absence (95% to 50%), and physical activity (+81% improvement).
Thus, durable transfusion independence and quality-of-life improvements were reported in patients with TDT who received beti-cel infusion therapy.
- Walters MC, et al. Long Term Outcomes of 63 Patients with Transfusion-Dependent β-Thalassemia (TDT) Followed up to 7 Years Post-Treatment with betibeglogene autotemcel (beti-cel) Gene Therapy and Exploratory Analysis of Predictors of Successful Treatment Outcomes in Phase 3 Trials. Abstract 2348, ASH 64th Annual Meeting, 10–13 December 2022, New Orleans, LA, USA.
- Locatelli F, et al. Long-Term Patient-Reported Outcomes Following Treatment with betibeglogene autotemcel in Patients with Transfusion-Dependent β-Thalassemia. Abstract 3665, ASH 64th Annual Meeting, 10–13 December 2022, New Orleans, LA, USA.
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« Neutrodiet: non-restricted diet is the preferred option after SCT Next Article
Durable responses to gene therapy in haemophilia A »
« Neutrodiet: non-restricted diet is the preferred option after SCT Next Article
Durable responses to gene therapy in haemophilia A »
Table of Contents: ASH 2022
Featured articles
Acute Lymphoblastic Leukaemia
Blinatumomab candidate for standard-of-care in newly diagnosed B-ALL
High-dose methotrexate or standard interim maintenance in young patients with ALL?
Acute Myeloid Leukaemia
Excellent results for triplet regimen in FLT3-mutated AML
MRD by qPCR prognostic of outcomes in venetoclax-treated NPM1-mutated AML
Promising results for triplet therapy with magrolimab in AML
Should we use intensive chemotherapy prior to allo-HCT in relapsed/refractory AML?
Chronic Leukaemia
Zanubrutinib wins battle of BTK inhibitors in relapsed or refractory CLL/SLL
Ibrutinib plus venetoclax displays long-term benefits in CLL
Multiple Myeloma
Talquetamab further investigated in heavily pre-treated MM after promising phase 2 data
Promising results of elranatamab for MM in phase 2 MagnetisMM-3 trial
Deep and durable responses for quadruple therapy in smouldering MM
Ultra-sensitive MRD assessment in MM with BloodFlow
CAR-Hematotox score proves useful in relapsed/refractory MM
Head-to-head: VMP versus Rd in transplant-ineligible MM
Lymphoma
Ibrutinib added to ASCT improves clinical outcomes in mantle cell lymphoma
High-dose chemotherapy plus ASCT superior to standard immuno-chemotherapy in primary CNS lymphoma
Odronextamab has considerable anti-tumour effects in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma
Excellent results for AFM13-complexed NK cells in CD30-positive lymphoma
CAR-Hematotox score predicts toxicity, infections, and clinical outcomes in MCL
Myeloproliferative Neoplasms
Efgartigimod successful in immune thrombocytopenia
INCA033989: novel investigational agent for CALR-mutated MPN
Ruxolitinib mediates clonal evolution of RAS pathway mutations in MPN
Immune Thrombocytopenia
Long-term risk for haematologic disease in persistent, isolated mild thrombocytopenia
Various Topics
C1 inhibitor deficiency linked to thrombosis
Durable responses to gene therapy in haemophilia A
Long-term benefits from beti-cel in transfusion-dependent β-thalassaemia
Neutrodiet: non-restricted diet is the preferred option after SCT
Iptacopan offers solution for patients with PNH and residual anaemia after standard-of-care
Novel therapy may replace standard-of-care prophylaxis for GVHD
LMWH does not result in higher live birth rates in women with inherited thrombophilia
Related Articles
February 20, 2023
C1 inhibitor deficiency linked to thrombosis
February 20, 2023
Durable responses to gene therapy in haemophilia A
February 20, 2023
Neutrodiet: non-restricted diet is the preferred option after SCT
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy